Tag Archives: Mara Goldstein

Mizuho Securities Remains a Buy on Autolus Therapeutics (AUTL)

Mizuho Securities analyst Mara Goldstein maintained a Buy rating on Autolus Therapeutics (AUTL – Research Report) today and set a price target of $24.00. The company’s shares closed last Thursday at $15.87, close to its 52-week high of $17.19. According

Analysts Offer Insights on Healthcare Companies: Xencor (NASDAQ: XNCR) and Invitae (NYSE: NVTA)

There’s a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on Xencor (XNCR – Research Report) and Invitae (NVTA – Research Report) with bullish sentiments. Xencor (XNCR) In a report released yesterday, Mara

Mizuho Securities Sticks to Their Buy Rating for Merck & Company (MRK)

In a report released today, Mara Goldstein from Mizuho Securities maintained a Buy rating on Merck & Company (MRK – Research Report), with a price target of $100.00. The company’s shares closed last Friday at $80.24. According to TipRanks.com, Goldstein

Mizuho Securities Keeps a Buy Rating on Corvus Pharmaceuticals (CRVS)

In a report released yesterday, Mara Goldstein from Mizuho Securities maintained a Buy rating on Corvus Pharmaceuticals (CRVS – Research Report), with a price target of $7.00. The company’s shares closed last Thursday at $4.27. According to TipRanks.com, Goldstein ‘s

Mizuho Securities Believes Neoleukin Therapeutics (NASDAQ: NLTX) Still Has Room to Grow

In a report released today, Mara Goldstein from Mizuho Securities initiated coverage with a Buy rating on Neoleukin Therapeutics (NLTX – Research Report) and a price target of $21.00. The company’s shares closed last Wednesday at $13.52, close to its

Mizuho Securities Reaffirms Their Buy Rating on CytomX Therapeutics (CTMX)

In a report released yesterday, Mara Goldstein from Mizuho Securities maintained a Buy rating on CytomX Therapeutics (CTMX – Research Report), with a price target of $16.00. The company’s shares closed last Friday at $8.86. According to TipRanks.com, Goldstein is